



## **TFF Pharmaceuticals to Present at the Investor Summit Virtual Conference on August 18, 2021**

August 5, 2021

AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will present a corporate overview at the Investor Summit Virtual Conference being held August 17 – 18, 2021.

Mr. Mattes will deliver his corporate presentation on August 18<sup>th</sup> from 2:45 to 3:15 pm Eastern Time.

Management will be available for one-on-one meetings to be held throughout the conference.

Investors can register here: [Q3 Investor Summit Investor Registration](#)

### **About TFF Pharmaceuticals' Thin Film Freezing technology platform**

TFF Pharmaceuticals' Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a "Brittle Matrix Particle," which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

### **About TFF Pharmaceuticals**

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company's website at <https://tffpharma.com>.

### **SAFE HARBOR**

This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the benefits of the Company's TFF platform and its dry powder versions of Voriconazole and Tacrolimus, and the Company's plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of its dry powder versions of Voriconazole and Tacrolimus, (ii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (v) those other risks disclosed in the section "Risk Factors" included in the Company's 2020 Annual Report on Form 10-K filed with the SEC on March 10, 2021. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

### **Company Contacts:**

Glenn Mattes  
President and CEO  
TFF Pharmaceuticals, Inc.  
[gmattes@tffpharma.com](mailto:gmattes@tffpharma.com)  
737-802-1973

Kirk Coleman  
Chief Financial Officer  
TFF Pharmaceuticals, Inc.  
[kcoleman@tffpharma.com](mailto:kcoleman@tffpharma.com)  
817-989-6358

### **Investor Relations Contact:**

Corey Davis, Ph.D.  
LifeSci Advisors  
212-915-2577  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

**Media Contact:**

Gwendolyn Schanker  
LifeSci Communications  
(269) 921-3607  
[gschanker@lifescicomms.com](mailto:gschanker@lifescicomms.com)



Source: TFF Pharmaceuticals, Inc.